iTeos Therapeutics, Inc. (NASDAQ:ITOS) Holdings Lowered by Intech Investment Management LLC

Intech Investment Management LLC trimmed its position in shares of iTeos Therapeutics, Inc. (NASDAQ:ITOS) by 15.1% during the 4th quarter, HoldingsChannel reports. The firm owned 12,811 shares of the company’s stock after selling 2,274 shares during the quarter. Intech Investment Management LLC’s holdings in iTeos Therapeutics were worth $98,000 at the end of the most recent quarter.

Other large investors have also recently bought and sold shares of the company. Point72 DIFC Ltd bought a new position in iTeos Therapeutics during the third quarter valued at approximately $31,000. Virtu Financial LLC bought a new stake in shares of iTeos Therapeutics in the third quarter valued at approximately $102,000. Quest Partners LLC grew its stake in shares of iTeos Therapeutics by 914.7% in the third quarter. Quest Partners LLC now owns 11,020 shares of the company’s stock worth $113,000 after acquiring an additional 9,934 shares during the last quarter. Clear Harbor Asset Management LLC bought a new position in iTeos Therapeutics during the fourth quarter worth $96,000. Finally, SG Americas Securities LLC raised its stake in iTeos Therapeutics by 12.2% during the 4th quarter. SG Americas Securities LLC now owns 13,866 shares of the company’s stock valued at $106,000 after purchasing an additional 1,508 shares during the last quarter. 97.16% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

ITOS has been the topic of several research analyst reports. Wells Fargo & Company decreased their price target on shares of iTeos Therapeutics from $19.00 to $17.00 and set an “overweight” rating on the stock in a research report on Thursday, March 6th. JPMorgan Chase & Co. decreased their target price on iTeos Therapeutics from $22.00 to $15.00 and set an “overweight” rating on the stock in a research report on Thursday, March 6th. Wedbush reaffirmed an “outperform” rating and issued a $25.00 price target on shares of iTeos Therapeutics in a report on Wednesday, March 5th. Finally, HC Wainwright reiterated a “buy” rating and set a $46.00 target price on shares of iTeos Therapeutics in a research report on Thursday, March 6th.

iTeos Therapeutics Stock Up 3.1 %

ITOS stock opened at $6.70 on Friday. iTeos Therapeutics, Inc. has a twelve month low of $6.32 and a twelve month high of $18.75. The company has a market cap of $255.90 million, a P/E ratio of -2.13 and a beta of 1.38. The business has a fifty day moving average of $7.30 and a 200-day moving average of $8.51.

iTeos Therapeutics (NASDAQ:ITOS) last released its earnings results on Wednesday, March 5th. The company reported ($1.01) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.14) by $0.13. As a group, equities research analysts anticipate that iTeos Therapeutics, Inc. will post -3.49 earnings per share for the current fiscal year.

About iTeos Therapeutics

iTeos Therapeutics, Inc is a clinical-stage biopharmaceutical company, which engages in the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. Its pipeline includes EOS-448, Inupadenant, and EOS-984. The company was founded by Michel Detheux in April 2012 and is headquartered in Watertown, MA.